

# **ePoster #20: Cannabidiol for Pain Control After Rotator Cuff Repair Demonstrates No Functional Deficits at 1-Year**

**Michael J. Alaia<sup>1</sup>, Zachary I. Li<sup>1</sup>, Isabel Chalem<sup>1</sup>, Eoghan T. Hurley<sup>1</sup>, Kinjal Vasavada<sup>1</sup>, Guillem Gonzalez-Lomas<sup>1</sup>, Andrew S. Rokito<sup>1</sup>, Laith M. Jazrawi<sup>1</sup>, Kevin Kaplan<sup>2</sup>**

<sup>1</sup>Department of Orthopedic Surgery, New York University Langone Health, New York, NY



<sup>2</sup>Jacksonville Orthopaedic Institute, Jacksonville, FL

# Disclosures

- Kevin M. Kaplan: Arthrex, Team 1 LLC, and Orcosa, Inc.
- Michael J. Alaia: Bodycad, DePuy Synthes, Arthrex, Gotham Surgical Solutions & Devices, Orcosa, Inc.
- Laith M. Jazrawi: Arthrex, Mitek, Smith & Nephew, and Wolters Kluwer Health
- Guillem Gonzalez-Lomas: Arthrex

# Background

- Cannabidiol (CBD) has recently demonstrated a positive impact on patient pain and satisfaction immediately after arthroscopic rotator cuff repair (ARCR)
- Despite increasing popularity of non-prescription CBD for pain treatment, there are limited high-quality studies investigating therapeutic effects and safety long-term
- Does the addition of CBD to a postoperative regimen cause any changes in clinical outcomes?



## Purpose

To evaluate 1-year functional outcomes among patients who previously underwent ARCR and received buccally absorbed cannabidiol or an identical placebo in early post-operative pain management.

## Hypothesis

There will be no significant differences in pain or shoulder function between those who received CBD vs placebo at 1-year follow-up.


# Methods

- Inclusion:
  - All opioid-naive patients ages 18-75 years undergoing ARCR who previously completed an FDA-sanctioned, multi-center, placebo-controlled, randomized, double-blinded trial evaluating the analgesic effects of CBD in immediate postoperative period
- Exclusion:
  - Marijuana users, preop opiates, abnormal coag history/VTE, stroke/ACS history 3 months preop, renal/liver failure, on medications with significant interaction with CYP pathway
- Randomization
  - Experimental group: 25-mg CBD TID if <80kg and 50-mg of CBD TID if >80kg for 14 days
  - Control group: Identical placebo

# Methods – Outcomes

- Patient-reported outcomes at minimum 1-year follow-up
  - Visual Analogue Scale (VAS) for pain
  - American Shoulder and Elbow Surgeons (ASES) score
  - Single Assessment Numeric Evaluation (SANE) score
  - Satisfaction (VAS)
- Statistical analyses
  - Mann-Whitney U test
  - Fischer's exact test
  - One-way ANOVA with Tukey's post-hoc testing (25-mg, 50-mg, placebo)

# Methods – CONSORT Flow Diagram



## Results – Demographics and Operative Characteristics

<i>VARIABLE</i>	<b>CBD</b>	<b>PLACEBO</b>	<i>P</i>
<b>Age at surgery (years)</b>	58.4 ± 9.5	57.5 ± 10.6	0.591
<b>Sex (female)</b>	15 (35.7)	14 (35.0)	0.946
<b>Body mass index</b>	28.9 ± 4.8	28.1 ± 7.6	0.659
<b>Biceps tenodesis</b>	7 (16.7)	11 (27.5)	0.236
<b>Subacromial decompression</b>	19 (45.2)	11 (27.5)	0.096
<b>Both biceps tenodesis and subacromial decompression</b>	10 (23.8)	16 (40.0)	0.115
<b>No. of anchors used</b>	3.3 ± 1.6	3.2 ± 1.4	0.660



# Results – Patient-Reported Outcomes

<i>Variable</i>	<b>CBD (n=42)</b>	<b>Placebo (n=40)</b>	<i>p</i>
<b>VAS Pain</b>	0.8 ± 1.6	1.2 ± 1.8	0.384
<b>ASES</b>	93.0 ± 13.9	91.1 ± 15.0	0.714
<b>Activities of daily living, subscore</b>	45.7 ± 7.4	46.2 ± 5.7	0.764
<b>Achieved PASS</b>	34 (81.0)	31 (77.5)	0.788
<b>SANE</b>	87.6 ± 12.2	90.1 ± 13.1	0.236
<b>Satisfaction</b>	97.4 ± 5.2	95.4 ± 9.9	0.408
<b>Surgery met expectations (Y/N)</b>	42 (100)	39 (97.5)	0.488
<b>Would be willing to repeat (Y/N)</b>	40 (95.2)	39 (97.5)	0.616

\*\*Secondary procedures: Three patients, one in the CBD group (2.4%) and two in the placebo group (5.0%), underwent arthroscopic revision following the index ARCR ( $p = 0.611$ )

## Results – Subgroup Analysis by Dose

<i>Variable</i>	<b>CBD 25-mg (n=16)</b>	<b>CBD 50-mg (n=26)</b>	<b>Placebo (n=40)</b>	<b>p</b>
<b>VAS Pain</b>	0.7 ± 1.4	0.9 ± 1.8	1.2 ± 1.8	0.632
<b>ASES</b>	93.4 ± 11.2	92.1 ± 15.8	91.1 ± 15.0	0.747
<b>Activities of daily living, subscore</b>	46.6 ± 5.3	45.2 ± 8.6	46.2 ± 5.7	0.753
<b>Achieved PASS</b>	13 (83.3)	21 (80.8)	31 (77.5)	0.928
<b>SANE</b>	87.3 ± 13.1	87.8 ± 11.9	90.1 ± 13.1	0.664
<b>Satisfaction</b>	97.6 ± 4.4	97.2 ± 5.7	95.4 ± 9.9	0.578
<b>Surgery met expectations (Y/N)</b>	16 (100)	26 (100)	39 (97.5)	0.603
<b>Would be willing to repeat (Y/N)</b>	16 (100)	24 (92.3)	39 (97.5)	0.150

\*Patients <80-kg received 25-mg TID and those >80-kg received the 50-mg dose.

# Limitations

- Patients were no longer blinded regarding which treatment group they were assigned in original study by the time of latest follow-up
  - They were not reminded of their allocation during follow-up unless specifically requested
- Patient-reported outcome scores were not collected preoperatively, so it was not possible to calculate the pre- to postoperative improvement
  - Original trial randomization would have accounted for differences in baseline function, and the current study was adequately powered to determine differences in clinical outcomes at 1-year follow-up
- Multiple orthopedic surgeons
  - However surgical technique was largely similar, and the postoperative protocol was uniform across patients in the study

# Conclusion

- Peri-operative use of CBD for pain control among patients undergoing ARCR *does not* result in any significant differences in patient-reported pain, satisfaction, or functional outcomes at least 1-year postoperatively compared to a placebo control
- CBD can be considered in a postoperative multimodal pain management regimen without detrimental effects on outcome.

# References

1. Alaia MJ, Hurley ET, Vasavada K, et al. Buccally Absorbed Cannabidiol Shows Significantly Superior Pain Control and Improved Satisfaction Immediately After Arthroscopic Rotator Cuff Repair: A Placebo-Controlled, Double-Blinded, Randomized Trial. *Am J Sports Med.* 2022;50(11):3056-3063.
2. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants.* 2019;9(1):21.
3. Barber FA. Triple-Loaded Single-Row Versus Suture-Bridge Double-Row Rotator Cuff Tendon Repair With Platelet-Rich Plasma Fibrin Membrane: A Randomized Controlled Trial. *Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2016;32(5):753-761.
4. Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem.* 1993;214(1):173-180.
5. Burks RT, Crim J, Brown N, Fink B, Greis PE. A prospective randomized clinical trial comparing arthroscopic single- and double-row rotator cuff repair: magnetic resonance imaging and early clinical evaluation. *Am J Sports Med.* 2009;37(4):674-682.
6. Chin G, Etiz BAF, Nelson AM, Lim PK, Scolaro JA. Knowledge and Opinion on Cannabinoids Among Orthopaedic Traumatologists. *JAAOS Glob Res Rev.* 2021;5(4):e21.00047.
7. Commissioner O of the. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. FDA.
8. Cvetanovich GL, Gowd AK, Liu JN, et al. Establishing clinically significant outcome after arthroscopic rotator cuff repair. *J Shoulder Elbow Surg.* 2019;28(5):939-948.
9. De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. *Pain.* 2019;160(1):136-150.
10. Decker DG, Doan M, Hassebrock JD, et al. Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients. *Orthop J Sports Med.* 2022;10(4):23259671221087628.
11. Fan N, Yuan S, Du P, et al. The effects of smoking on clinical and structural outcomes after rotator cuff repair: a systematic review and meta-analysis. *J Shoulder Elbow Surg.* 2022;31(3):656-667.
12. Gardener H, Wallin C, Bowen J. Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. *Sci Total Environ.* 2022;851(Pt 1):158110.
13. Haffar A, Khan IA, Abdelaal MS, Banerjee S, Sharkey PF, Lonner JH. Topical Cannabidiol (CBD) After Total Knee Arthroplasty Does Not Decrease Pain or Opioid Use: A Prospective Randomized Double-Blinded Placebo-Controlled Trial. *J Arthroplasty.* 2022;37(9):1763-1770.
14. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. *Eur J Pain Lond Engl.* 2016;20(6):936-948.
15. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. *Cannabis Cannabinoid Res.* 2017;2(1):139-154.
16. Jildeh TR, Abbas MJ, Hasan L, Moutzouros V, Okoroa KR. Multimodal Nonopioid Pain Protocol Provides Better or Equivalent Pain Control Compared to Opioid Analgesia Following Arthroscopic Rotator Cuff Surgery: A Prospective Randomized Controlled Trial. *Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2022;38(4):1077-1085.
17. Johnson E, Kilgore M, Babalonis S. Cannabidiol (CBD) product contamination: Quantitative analysis of  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) concentrations found in commercially available CBD products. *Drug Alcohol Depend.* 2022;237:109522.
18. Kroenke K, Cheville A. Management of Chronic Pain in the Aftermath of the Opioid Backlash. *JAMA.* 2017;317(23):2365-2366.
19. Manzanares J, Julian M, Carrascosa A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. *Curr Neuropharmacol.* 2006;4(3):239-257.
20. Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. *Sports Health.* 2020;12(6):540-546.
21. Miller H, De Leo N, Badach J, et al. Role of marijuana components on the regenerative ability of stem cells. *Cell Biochem Funct.* 2021;39(3):432-441.
22. Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. *Int J Mol Sci.* 2020;21(22):8870.
23. Morris BJ, Mir HR. The Opioid Epidemic: Impact on Orthopaedic Surgery. *JAAOS - J Am Acad Orthop Surg.* 2015;23(5):267-271.
24. Moutzouros V, Jildeh TR, Khalil LS, et al. A Multimodal Protocol to Diminish Pain Following Common Orthopedic Sports Procedures: Can We Eliminate Postoperative Opioids? *Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc.* 2020;36(8):2249-2257.
25. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature.* 1993;365(6441):61-65.

# #1 in the U.S. for Quality and Safety #1 Hospital in New York

## NYU Langone Orthopedics

### By the Numbers



#### Clinical

**34,000+**

surgical  
procedures  
performed  
annually



**450,000+**

office visits annually

#### Advanced Technology

30+ robotics  
and navigation  
platforms systemwide



#### Education

**Largest and  
one of the  
most diverse**

orthopedic residency  
programs in the  
United States



**87**

residents across  
two accredited programs

**21**

fellows across  
six specialty programs



#### Research



**#8**

in NIH funding  
for orthopedic  
surgery



**350+**

peer-reviewed  
publications  
annually